Abbott takes DexCom to court
This article was originally published in The Gray Sheet
Executive Summary
Patent infringement complaint filed by Abbott in a Delaware district court alleges that DexCom's continuous glucose monitor system is derived from Abbott's patents. Both DexCom (STS) and Abbott (Freestyle Navigator) are vying to reach the U.S. market. DexCom responds that since neither product is commercialized, the firm is "not harming Abbott's current glucose monitoring business in any manner" and that Abbott could not have been able to scientifically investigate the STS. DexCom filed for PMA approval in March (1"The Gray Sheet" Aug. 8, 2005, p. 20)...
You may also be interested in...
DexCom Glucose Monitoring Systems Progress Toward FDA Approval
A recently completed 86-patient study will support DexCom's anticipated PMA application for theSTS seven-day continuous glucose monitoring system
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.